First patent from a new patent family granted in China, strengthening the long‑term intellectual property protection for the Company’s lead product candidate Oslo, Norway, 19 March 2026: Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces […]
Internationally recognized radiopharmaceutical leader joins Actithera as the lead FAP-targeting asset advances to clinical development and the differentiated pipeline takes shape Brings over 15 years of global oncology and hematology leadership, advancing over 10 radioligands across the development spectrum, from preclinical to Phase III Oslo, Norway and Cambridge, Massachusetts — 3 December 2025 — […]
NorthStar will supply non-carrier added Actinium-225, a radionuclide, for use with Ariceum’s first-in-class radiopharmaceutical drug, satoreotide Berlin, Germany, and Beloit, Wisconsin, 11 December 2024 – Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization […]
Berlin, Germany, December 5, 2024 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and Eckert & Ziegler, one of the world’s largest providers of isotopes for medical, scientific and industrial use, today announced the signing of a global supply agreement for the medical radionuclides […]
225Ac-Satoreotide is a first-in-class somatostatin receptor 2 antagonist targeting extensive stage small cell lung cancer and is the first antagonist labelled with 225Ac to enter clinical development Satoreotide expressed a superior pharmacokinetic profile relative to DOTA-TATE with a higher pre-clinical anti-tumour efficacy, irrespective of radionuclide used 100% survival with a single dose of 30 kBq 225Ac-satoreotide but […]
